levonorgestrel has been researched along with spironolactone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Liu, X; Pepe, SR | 1 |
| de Zegher, F; Del Río, L; Díaz, M; Ibáñez, L; López-Bermejo, A; Pozo, ÓJ; Sebastiani, G | 1 |
| Badmus, OO; Olatunji, LA | 1 |
| Cereijo, R; de Zegher, F; García-Beltran, C; Ibáñez, L; López-Bermejo, A; Malpique, R; Quesada-López, T; Villarroya, F | 1 |
1 review(s) available for levonorgestrel and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for levonorgestrel and spironolactone
| Article | Year |
|---|---|
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism; Humans; Hypoglycemic Agents; Infertility, Female; Intra-Abdominal Fat; Levonorgestrel; Metformin; Oligomenorrhea; Ovulation; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Thiazolidinediones | 2017 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemokines, CXC; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Ethinyl Estradiol; Female; Gene Expression; Genetic Diseases, X-Linked; Gigantism; Heart Defects, Congenital; Humans; Hypoglycemic Agents; Insulin Resistance; Intellectual Disability; Levonorgestrel; Metformin; Mineralocorticoid Receptor Antagonists; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone; Treatment Outcome | 2020 |
5 other study(ies) available for levonorgestrel and spironolactone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
The association between drospirenone and hyperkalemia: a comparative-safety study.
Topics: Adult; Androstenes; Cohort Studies; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Follow-Up Studies; Humans; Hyperkalemia; Levonorgestrel; Logistic Models; Proportional Hazards Models; Retrospective Studies; Risk Factors; Spironolactone | 2011 |
Involvement of glucocorticoid and mineralocorticoid receptors in lipid accumulation and depressed G6PD activity in the livers of rats treated with postpartum oral estrogen-progestin.
Topics: Animals; Contraceptives, Oral, Hormonal; Estrogens; Ethinyl Estradiol; Female; Glucose; Glucosephosphate Dehydrogenase; Levonorgestrel; Lipid Metabolism; Liver; Mifepristone; Mineralocorticoid Receptor Antagonists; Pregnancy; Progestins; Rats; Rats, Wistar; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone | 2019 |